OriolaCHIX:ORIOLH 38 EV-to-EBIT is 16.10 as of Jul. 08, 2026, which is 18% below its 10-year median of 19.70. GuruFocus rates CHIX:ORIOLH with a GF Score™ of 38/100 and a GF Value™ of €0.99. The stock has 5 warning signs investors should review. Among 469 Healthcare Providers & Services companies, Oriola ranks worse than 51.6% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Oriola's Enterprise Value is €118 Mil.
Oriola's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €7 Mil. Therefore, Oriola's EV-to-EBIT for today is 16.10.
The historical rank and industry rank for Oriola's EV-to-EBIT or its related term are showing as below:
CHIX:ORIOLh'
s EV-to-EBIT Range Over the Past 10 Years
Min: -523.69 Med: 19.7 Max: 99999999.99
Current: 16.11
During the past 13 years, the highest EV-to-EBIT of Oriola was 99999999.99. The lowest was -523.69. And the median was 19.70.
CHIX:ORIOLh's EV-to-EBIT is ranked worse than 51.6% of 469
companies
in the Healthcare Providers & Services industry
Industry Median: 15.77
vs CHIX:ORIOLh: 16.11
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Oriola's Enterprise Value for the quarter that ended in Mar. 2026 was €117 Mil.
Oriola's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oriola EV-to-EBIT Related Terms
Oriola EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Oriola's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Oriola's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oriola EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Oriola's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Oriola's EV-to-EBIT falls into.
Oriola's current Enterprise Value is €118 Mil.
Oriola's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oriola (CHIX:ORIOLH) has a EV-to-EBIT of 16.10 as of Jul. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oriola and its competitors. This is 18% below median its historical median of 19.70. According to the industry distribution chart, Oriola ranks #242 out of 469 companies in the Healthcare Providers & Services industry, placing it in the top 51.6%.
Is Oriola's EV-to-EBIT too high?
Oriola's current EV-to-EBIT of 16.10 is 18% below median its 10-year median of 19.70. The Healthcare Providers & Services industry median EV-to-EBIT is 15.77. Oriola's value of 16.10 is 2.1% above this industry median. Based on the distribution chart, Oriola ranks #242 out of 469 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Oriola has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Oriola's EV-to-EBIT compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Oriola ranks #242 out of 469 companies for EV-to-EBIT. This places Oriola in the lower half of its industry. The industry median EV-to-EBIT is 15.77. Oriola's value of 16.10 is 2.1% above this benchmark. While the company's 10-year median is 19.70 vs. the industry median of 15.77, Oriola has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.77, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oriola's current EV-to-EBIT of 16.10 is 2.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Oriola and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oriola's current EV-to-EBIT is 16.10, which is 18% below median its own 10-year median of 19.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oriola stock overvalued right now?
Oriola (CHIX:ORIOLH) has a current EV-to-EBIT of 16.10. The stock's GF Value™ is €0.99, compared to a current price of €0.94 — trading 5.3% below its estimated fair value. The current EV-to-EBIT is 16.10, which is 18% below median its 10-year median of 19.70 and 2.1% above the Healthcare Providers & Services industry median of 15.77. Oriola's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Oriola (CHIX:ORIOLH), the current EV-to-EBIT is 16.10 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oriola (CHIX:ORIOLH) Overvalued in 2026?
Based on GuruFocus' analysis, Oriola stock appears to be undervalued.
The current stock price of €0.94 is trading 5.3% below its estimated GF Value™ of €0.99.
Key valuation signals for CHIX:ORIOLH:
EV-to-EBIT: 16.10 (18% below median its 10-year median of 19.70)
GF Value™: €0.99 vs. price of €0.94 (5.3% below fair value)
Industry Position: 2.1% above the Healthcare Providers & Services median (#242 of 469)
No single metric tells the full story. See the CHIX:ORIOLH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oriola Corp is a health and wellbeing company operating in Nordic countries. It offers services such as the distribution of pharmaceuticals and other health and well-being products, services, and dose dispensing. Oriola's operations are divided into two segments which include distribution and wholesale. Geographically, the company operates in Sweden, Finland and other countries generating majority revenue from the region of Sweden.
38GF Score
Get the complete analysis for CHIX:ORIOLH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ORIOLH has been successfully added to your 
